Next-generation sequencing identifies germline MRE11A variants as markers of radiotherapy outcomes in muscle-invasive bladder cancer

por Teo, M. T. W., Dyrskjøt, L., Nsengimana, J., Buchwald, C., Snowden, H., Morgan, J., Jensen, J. B., Knowles, M. A., Taylor, G., Barrett, J. H., Borre, M., Ørntoft, T. F., Bishop, D. T., Kiltie, A. E.
Publicado 2014

Intensity-modulated Radiotherapy for Rectal Cancer in the UK in 2020

por Hanna, C.R., Slevin, F., Appelt, A., Beavon, M., Adams, R., Arthur, C., Beasley, M., Duffton, A., Gilbert, A., Gollins, S., Harrison, M., Hawkins, M.A., Laws, K., O'Cathail, S., Porcu, P., Robinson, M., Sebag-Montefiore, D., Teo, M., Teoh, S., Muirhead, R.
Publicado 2021

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)

por Grivas, P., Loriot, Y., Morales-Barrera, R., Teo, M. Y., Zakharia, Y., Feyerabend, S., Vogelzang, N. J., Grande, E., Adra, N., Alva, A., Necchi, A., Rodriguez-Vida, A., Gupta, S., Josephs, D. H., Srinivas, S., Wride, K., Thomas, D., Simmons, A., Loehr, A., Dusek, R. L., Nepert, D., Chowdhury, S.
Publicado 2021